New-onset systemic sclerosis and scleroderma renal crisis under docetaxel.
Fiche publication
Date publication
octobre 2021
Journal
Journal of scleroderma and related disorders
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARTIN Thierry
Tous les auteurs :
Debien V, Petitdemange A, Bazin D, Ederle C, Nespola B, Merdji H, Olagne J, Martin T, Guffroy A, Pflumio C
Lien Pubmed
Résumé
Systemic sclerosis is a rare systemic autoimmune disease characterized by microvascular impairment and fibrosis of the skin and other organs with poor outcomes. Toxic causes may be involved. We reported the case of a 59-year-old woman who developed an acute systemic sclerosis after two doses of adjuvant chemotherapy by docetaxel and cyclophosphamide for a localized hormone receptor + human epithelial receptor 2-breast cancer. Docetaxel is a major chemotherapy drug used in the treatment of breast, lung, and prostate cancers, among others. Scleroderma-like skin-induced changes (morphea) have been already described for taxanes. Here, we report for the first time a case of severe lung and kidney flare with thrombotic microangiopathy after steroids for acute interstitial lung disease probably induced by anti-RNA polymerase III + systemic sclerosis after docetaxel.
Mots clés
Docetaxel, chemotherapy, drug-induced autoimmune disease, paraneoplastic, scleroderma, systemic sclerosis
Référence
J Scleroderma Relat Disord. 2021 Oct;6(3):306-310